Part 4: Interaction between unproven cellular therapies and global medicinal product approval regulatory frameworks.

导出 LinkOut

翻译打印收藏纠错

作者： Karen,Nichols ^[1] ; William,Janssen ^[2] ; Dominic,Wall ^[3] ; Natividad,Cuende ^[4] ; Deborah,Griffin ^[5]

作者单位： NantKwest, Inc, Culver City, California, USA. ISCT Past Co-Chair, NA LRA Committee 2011-2014. Electronic address: beinc897@gmail.com. ^[1] St Jude Children's Research Hospital, Memphis, Tennessee, USA. ISCT Past Co-Chair, NA LRA Committee 2011-2014. ISCT North America, Regional Vice-President 2014-2016. ^[2] Department of Pathology, University of Melbourne; Cell Therapies Pty Ltd, East Melbourne, Australia, ISCT Australia & New Zealand, Past Regional Vice President 2012-2014 and Chair, ISCT ANZ LRA Committee 2014-2016. ^[3] Andalusian Initiative for Advanced Therapies, Junta de Andalucía, Sevilla, Spain. Chair, ISCT EU LRA Committee 2014-2016. ^[4] Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Chair, ISCT NA LRA Committee 2014-2016. Co-Editor of the Telegraft. ^[5]

DOI 10.1016/j.jcyt.2015.11.003

PMID 26719205

发布时间 2015-12-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览9

Cytotherapy

2016年18卷1期

127-37页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Part 4: Interaction between unproven cellular therapies and global medicinal product approval regulatory frameworks.

Cytotherapy

相似文献

Cytotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Part 4: Interaction between unproven cellular therapies and global medicinal product approval regulatory frameworks.

Cytotherapy

相似文献

Cytotherapy

相关期刊

检索历史清除